{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T20:06:51Z","timestamp":1787861211805,"version":"build-2784847793"},"reference-count":45,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,1,18]],"date-time":"2022-01-18T00:00:00Z","timestamp":1642464000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["annallergy.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Allergy, Asthma & Immunology"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1016\/j.anai.2021.12.020","type":"journal-article","created":{"date-parts":[[2022,1,21]],"date-time":"2022-01-21T11:54:24Z","timestamp":1642766064000},"page":"352-360","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"title":["Understanding the role of long-acting muscarinic antagonists in asthma treatment"],"prefix":"10.1016","volume":"128","author":[{"given":"Susan","family":"Muiser","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reinoud","family":"Gosens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maarten","family":"van den Berge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huib A.M.","family":"Kerstjens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.anai.2021.12.020_bib0001","series-title":"Goodman and Gilman's: The Pharmacological Basis of Therapeutics","article-title":"Muscarinic receptor agonists and antagonists","author":"Brown","year":"1996"},{"key":"10.1016\/j.anai.2021.12.020_bib0002","first-page":"665","article-title":"Treatment of asthma","volume":"5","author":"Courty","year":"1859","journal-title":"Edin J"},{"issue":"5145","key":"10.1016\/j.anai.2021.12.020_bib0003","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1136\/bmj.2.5145.167","article-title":"Atropine cigarettes in asthma and emphysema","volume":"2","author":"Herxheimer","year":"1959","journal-title":"Br Med J"},{"issue":"2","key":"10.1016\/j.anai.2021.12.020_bib0004","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1017\/S0025727300000235","article-title":"\u201cDivine stramonium\u201d: the rise and fall of smoking for asthma","volume":"54","author":"Jackson","year":"2010","journal-title":"Med Hist"},{"issue":"8","key":"10.1016\/j.anai.2021.12.020_bib0005","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1056\/NEJM198808253190806","article-title":"Ipratropium bromide","volume":"319","author":"Gross","year":"1988","journal-title":"N Engl J Med"},{"key":"10.1016\/j.anai.2021.12.020_bib0006","series-title":"Anesthesia Secrects","first-page":"9","article-title":"Autonomic nervous system","author":"Duke","year":"2010"},{"issue":"4","key":"10.1016\/j.anai.2021.12.020_bib0007","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1513\/pats.200409-045MS","article-title":"Distribution of receptor targets in the lung","volume":"1","author":"Barnes","year":"2004","journal-title":"Proc Am Thorac Soc"},{"issue":"1","key":"10.1016\/j.anai.2021.12.020_bib0008","article-title":"Long-acting muscarinic antagonists (LAMA) added to combination long-acting beta2-agonists and inhaled corticosteroids (LABA\/ICS) versus LABA\/ICS for adults with asthma","volume":"1","author":"Kew","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.anai.2021.12.020_bib0009","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.ejim.2021.01.027","article-title":"Inhaled long-acting muscarinic antagonists in asthma - a narrative review","volume":"85","author":"Papi","year":"2021","journal-title":"Eur J Intern Med"},{"issue":"24","key":"10.1016\/j.anai.2021.12.020_bib0010","doi-asserted-by":"crossref","first-page":"2466","DOI":"10.1001\/jama.2021.7872","article-title":"Triple vs dual inhaler therapy and asthma outcomes in moderate to severe asthma: a systematic review and meta-analysis","volume":"325","author":"Kim","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.anai.2021.12.020_bib0011","unstructured":"Global initiative for asthma. Global strategy for asthma management and prevention. 2021. Available at: https:\/\/ginasthma.org\/wp-content\/uploads\/2021\/05\/GINA-Main-Report-2021-V2-WMS.pdf. Accessed August 5, 2021."},{"key":"10.1016\/j.anai.2021.12.020_bib0012","unstructured":"National Asthma Education and Prevention Program. Recommendations for the use of long-acting muscarinic antagonists for asthma. 2020. Available at: https:\/\/www.nhlbi.nih.gov\/health-topics\/all-publications-and-resources\/2020-focused-updates-asthma-management-guidelines. Accessed August 5, 2021."},{"issue":"3","key":"10.1016\/j.anai.2021.12.020_bib0013","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.tips.2014.11.005","article-title":"Acetylcholine beyond bronchoconstriction: roles in inflammation and remodeling","volume":"36","author":"Kistemaker","year":"2015","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.anai.2021.12.020_bib0014","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/1465-9921-7-73","article-title":"Muscarinic receptor signaling in the pathophysiology of asthma and COPD","volume":"7","author":"Gosens","year":"2006","journal-title":"Respir Res"},{"issue":"6","key":"10.1016\/j.anai.2021.12.020_bib0015","doi-asserted-by":"crossref","first-page":"7703","DOI":"10.1096\/fj.202000170R","article-title":"Cholinergic neuroplasticity in asthma driven by TrkB signaling","volume":"34","author":"Dragunas","year":"2020","journal-title":"Faseb J"},{"key":"10.1016\/j.anai.2021.12.020_bib0016","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1159\/000336498","article-title":"Role of parasympathetic nerves and muscarinic receptors in allergy and asthma","volume":"98","author":"Scott","year":"2012","journal-title":"Chem Immunol Allergy"},{"issue":"4","key":"10.1016\/j.anai.2021.12.020_bib0017","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01247-2017","article-title":"The mode of action of anticholinergics in asthma","volume":"52","author":"Gosens","year":"2018","journal-title":"Eur Respir J"},{"issue":"208","key":"10.1016\/j.anai.2021.12.020_bib0018","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/978-3-642-23274-9_14","article-title":"Muscarinic receptor antagonists: effects on pulmonary function","volume":"208","author":"Buels","year":"2012","journal-title":"Handb Exp Pharmacol"},{"issue":"2","key":"10.1016\/j.anai.2021.12.020_bib0019","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1124\/jpet.109.152470","article-title":"Preclinical evaluation of long-acting muscarinic antagonists: comparison of TIO and investigational drugs","volume":"330","author":"Casarosa","year":"2009","journal-title":"J Pharmacol Exp Ther"},{"issue":"2","key":"10.1016\/j.anai.2021.12.020_bib0020","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1124\/jpet.112.202051","article-title":"Pharmacological characterization of GSK573719 (umeclidinium): a novel, long-acting, inhaled antagonist of the muscarinic cholinergic receptors for treatment of pulmonary diseases","volume":"345","author":"Salmon","year":"2013","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.anai.2021.12.020_bib0021","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pupt.2015.11.004","article-title":"Interaction between corticosteroids and muscarinic antagonists in human airways","volume":"36","author":"Cazzola","year":"2016","journal-title":"Pulm Pharmacol Ther"},{"issue":"13","key":"10.1016\/j.anai.2021.12.020_bib0022","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1056\/NEJMoa1208606","article-title":"TIO in asthma poorly controlled with standard combination therapy","volume":"367","author":"Kerstjens","year":"2012","journal-title":"N Engl J Med"},{"issue":"10210","key":"10.1016\/j.anai.2021.12.020_bib0023","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1016\/S0140-6736(19)32215-9","article-title":"Single inhaler extrafine triple therapy in uncontrolled asthma (TRIMARAN and TRIGGER): two double-blind, parallel-group, randomised, controlled phase 3 trials","volume":"394","author":"Virchow","year":"2019","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.anai.2021.12.020_bib0024","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1016\/S2213-2600(20)30190-9","article-title":"Once-daily, single-inhaler MOM-IND-GLY versus MOM-IND or twice-daily fluticasone-SAL in patients with inadequately controlled asthma (iridium): a randomised, double-blind, controlled phase 3 study","volume":"8","author":"Kerstjens","year":"2020","journal-title":"Lancet Respir Med"},{"issue":"1","key":"10.1016\/j.anai.2021.12.020_bib0025","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S2213-2600(20)30389-1","article-title":"Efficacy and safety of once-daily single-inhaler triple therapy (FF\/UMEC\/VI) versus FF\/VI in patients with inadequately controlled asthma (Captain): a double-blind, randomised, phase 3A trial","volume":"9","author":"Lee","year":"2021","journal-title":"Lancet Respir Med"},{"issue":"18","key":"10.1016\/j.anai.2021.12.020_bib0026","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1056\/NEJMoa1008770","article-title":"TIO bromide step-up therapy for adults with uncontrolled asthma","volume":"363","author":"Peters","year":"2010","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.anai.2021.12.020_bib0027","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/S2213-2600(15)00031-4","article-title":"TIO or SAL as add-on therapy to inhaled corticosteroids for patients with moderate symptomatic asthma: two replicate, double-blind, placebo-controlled, parallel-group, active-comparator, randomised trials","volume":"3","author":"Kerstjens","year":"2015","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.anai.2021.12.020_bib0028","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2020.106021","article-title":"Fixed-dose combination of IND\/GLY\/MOM furoate once-daily versus SAL\/fluticasone twice-daily plus TIO once-daily in patients with uncontrolled asthma: a randomised, Phase IIIb, non-inferiority study (argon)","volume":"170","author":"Gessner","year":"2020","journal-title":"Respir Med"},{"issue":"1","key":"10.1016\/j.anai.2021.12.020_bib0029","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/s41030-020-00113-w","article-title":"Comparative responses in lung function measurements with TIO in adolescents and adults, and across asthma severities: a post hoc analysis","volume":"6","author":"Halpin","year":"2020","journal-title":"Pulm Ther"},{"issue":"3","key":"10.1016\/j.anai.2021.12.020_bib0030","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/j.jaip.2017.08.037","article-title":"TIO Respimat add-on is efficacious in symptomatic asthma, independent of T2 phenotype","volume":"6","author":"Casale","year":"2018","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"1","key":"10.1016\/j.anai.2021.12.020_bib0031","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1186\/s12931-020-01558-y","article-title":"Determinants of response to inhaled extrafine triple therapy in asthma: analyses of TRIMARAN and TRIGGER","volume":"21","author":"Singh","year":"2020","journal-title":"Respir Res"},{"issue":"1","key":"10.1016\/j.anai.2021.12.020_bib0032","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.pupt.2012.07.003","article-title":"Muscarinic receptors on airway mesenchymal cells: novel findings for an ancient target","volume":"26","author":"Meurs","year":"2013","journal-title":"Pulm Pharmacol Ther"},{"issue":"7","key":"10.1016\/j.anai.2021.12.020_bib0033","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1136\/thoraxjnl-2014-205731","article-title":"TIO attenuates IL-13-induced goblet cell metaplasia of human airway epithelial cells","volume":"70","author":"Kistemaker","year":"2015","journal-title":"Thorax"},{"issue":"4","key":"10.1016\/j.anai.2021.12.020_bib0034","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1183\/09031936.00004907","article-title":"Inhibition of allergen-induced airway remodelling by TIO and budesonide: a comparison","volume":"30","author":"Bos","year":"2007","journal-title":"Eur Respir J"},{"issue":"12","key":"10.1016\/j.anai.2021.12.020_bib0035","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1016\/j.bcp.2006.07.025","article-title":"Synergistic effects of the anti-cholinergic R,R-glycopyrrolate with anti-inflammatory drugs","volume":"72","author":"Pahl","year":"2006","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.anai.2021.12.020_bib0036","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s12931-016-0327-6","article-title":"Combination therapy of TIO and ciclesonide attenuates airway inflammation and remodeling in a guinea pig model of chronic asthma","volume":"17","author":"Kistemaker","year":"2016","journal-title":"Respir Res"},{"key":"10.1016\/j.anai.2021.12.020_bib0037","unstructured":"ClinicalTrials.gov. Evaluation of the anti-inflammatory effects of GLY added to IND\/MOM on the allergen-induced late asthmatic response. 2020. Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04259164. Accessed November 5, 2021."},{"issue":"1","key":"10.1016\/j.anai.2021.12.020_bib0038","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.jaip.2015.08.017","article-title":"The effect of TIO in symptomatic asthma despite low- to medium-dose inhaled corticosteroids: a randomized controlled trial","volume":"4","author":"Paggiaro","year":"2016","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"21","key":"10.1016\/j.anai.2021.12.020_bib0039","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1056\/NEJMoa1814917","article-title":"MOM or TIO in mild asthma with a low sputum eosinophil level","volume":"380","author":"Lazarus","year":"2019","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.anai.2021.12.020_bib0040","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1016\/j.jaip.2020.09.066","article-title":"A randomized, noninferiority trial comparing ICS\u00a0+\u00a0LABA with ICS\u00a0+\u00a0LABA\u00a0+\u00a0LAMA in asthma-COPD overlap (ACO) treatment: the ACO treatment with optimal medications (ATOMIC) study","volume":"9","author":"Park","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"5","key":"10.1016\/j.anai.2021.12.020_bib0041","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1183\/09031936.00040712","article-title":"Efficacy and safety of NVA237 versus placebo and TIO in patients with COPD: the GLOW2 study","volume":"40","author":"Kerwin","year":"2012","journal-title":"Eur Respir J"},{"issue":"1","key":"10.1016\/j.anai.2021.12.020_bib0042","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/s41533-020-00205-9","article-title":"Comparing LAMA with LABA and LTRA as add-on therapies in primary care asthma management","volume":"30","author":"Kaplan","year":"2020","journal-title":"NPJ Prim Care Respir Med"},{"key":"10.1016\/j.anai.2021.12.020_bib0043","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.rmed.2018.08.014","article-title":"TIO add-on to inhaled corticosteroids versus addition of long-acting \u03b2 2-agonists for adults with asthma","volume":"143","author":"Buhl","year":"2018","journal-title":"Respir Med"},{"key":"10.1016\/j.anai.2021.12.020_bib0044","doi-asserted-by":"crossref","unstructured":"Spain CV, Dayal P, Ding Y, Iribarren C, Omachi TA, Chen H. Usage of long-acting muscarinic antagonists and biologics as add-on therapy for patients in the United States with moderate-to-severe asthma [e-pub ahead of print]. J Asthma. https:\/\/doi.org\/10.1080\/02770903.2021.1922915, Accessed November 5, 2021.","DOI":"10.1080\/02770903.2021.1922915"},{"key":"10.1016\/j.anai.2021.12.020_bib0045","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/7473690","article-title":"Managing severe asthma: a role for the long-acting muscarinic antagonist TIO","volume":"2018","author":"Hamelmann","year":"2018","journal-title":"BioMed Res Int"}],"container-title":["Annals of Allergy, Asthma & Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1081120622000175?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1081120622000175?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T13:28:33Z","timestamp":1761053313000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1081120622000175"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":45,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["S1081120622000175"],"URL":"https:\/\/doi.org\/10.1016\/j.anai.2021.12.020","relation":{},"ISSN":["1081-1206"],"issn-type":[{"value":"1081-1206","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Understanding the role of long-acting muscarinic antagonists in asthma treatment","name":"articletitle","label":"Article Title"},{"value":"Annals of Allergy, Asthma & Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.anai.2021.12.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 American College of Allergy, Asthma & Immunology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}